Janney Montgomery Scott LLC Raises Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Janney Montgomery Scott LLC lifted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 39.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,079,281 shares of the company’s stock after acquiring an additional 588,295 shares during the quarter. Janney Montgomery Scott LLC owned 0.18% of Teva Pharmaceutical Industries worth $31,959,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in TEVA. Asset Management One Co. Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 14.6% in the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock worth $10,414,000 after acquiring an additional 58,413 shares during the period. Principal Financial Group Inc. grew its stake in shares of Teva Pharmaceutical Industries by 3.1% in the fourth quarter. Principal Financial Group Inc. now owns 92,471 shares of the company’s stock worth $2,038,000 after acquiring an additional 2,752 shares during the period. Sanctuary Advisors LLC grew its stake in shares of Teva Pharmaceutical Industries by 132.4% in the fourth quarter. Sanctuary Advisors LLC now owns 81,643 shares of the company’s stock worth $1,799,000 after acquiring an additional 46,514 shares during the period. CIBC Asset Management Inc grew its stake in shares of Teva Pharmaceutical Industries by 14.1% in the fourth quarter. CIBC Asset Management Inc now owns 120,328 shares of the company’s stock worth $2,652,000 after acquiring an additional 14,865 shares during the period. Finally, D.A. Davidson & CO. grew its stake in shares of Teva Pharmaceutical Industries by 2.8% in the fourth quarter. D.A. Davidson & CO. now owns 88,919 shares of the company’s stock worth $1,960,000 after acquiring an additional 2,408 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, May 8th. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a “buy” rating and a $25.00 target price for the company. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Thursday, May 22nd. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Nine investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and a consensus price target of $24.44.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $16.90 on Wednesday. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a market capitalization of $19.38 billion, a P/E ratio of -14.69, a P/E/G ratio of 0.90 and a beta of 0.60. The firm’s 50 day simple moving average is $16.18 and its two-hundred day simple moving average is $17.42.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The firm had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same quarter in the previous year, the firm earned $0.48 earnings per share. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Matthew Shields sold 6,206 shares of the company’s stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president now owns 9,989 shares of the company’s stock, valued at $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.